These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 22389738

  • 41. Innate Immune Basis for Rift Valley Fever Susceptibility in Mouse Models.
    Lathan R, Simon-Chazottes D, Jouvion G, Godon O, Malissen M, Flamand M, Bruhns P, Panthier JJ.
    Sci Rep; 2017 Aug 02; 7(1):7096. PubMed ID: 28769107
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector.
    Kortekaas J, de Boer SM, Kant J, Vloet RP, Antonis AF, Moormann RJ.
    Vaccine; 2010 Jun 17; 28(27):4394-401. PubMed ID: 20434545
    [Abstract] [Full Text] [Related]

  • 44. Rift Valley fever virus MP-12 vaccine encoding Toscana virus NSs retains neuroinvasiveness in mice.
    Indran SV, Lihoradova OA, Phoenix I, Lokugamage N, Kalveram B, Head JA, Tigabu B, Smith JK, Zhang L, Juelich TL, Gong B, Freiberg AN, Ikegami T.
    J Gen Virol; 2013 Jul 17; 94(Pt 7):1441-1450. PubMed ID: 23515022
    [Abstract] [Full Text] [Related]

  • 45. [Study on DNA immune of envelope protein gene of Rift Valley Fever Virus].
    Wang QH, Wang XJ, Hu S, Ge JY, Bu ZG.
    Wei Sheng Wu Xue Bao; 2007 Aug 17; 47(4):677-81. PubMed ID: 17944371
    [Abstract] [Full Text] [Related]

  • 46. Mutation of adjacent cysteine residues in the NSs protein of Rift Valley fever virus results in loss of virulence in mice.
    Monteiro GER, Jansen van Vuren P, Wichgers Schreur PJ, Odendaal L, Clift SJ, Kortekaas J, Paweska JT.
    Virus Res; 2018 Apr 02; 249():31-44. PubMed ID: 29530722
    [Abstract] [Full Text] [Related]

  • 47. Productive Propagation of Rift Valley Fever Phlebovirus Vaccine Strain MP-12 in Rousettus aegyptiacus Fruit Bats.
    Balkema-Buschmann A, Rissmann M, Kley N, Ulrich R, Eiden M, Groschup MH.
    Viruses; 2018 Nov 30; 10(12):. PubMed ID: 30513679
    [Abstract] [Full Text] [Related]

  • 48. Attenuation of pathogenic Rift Valley fever virus strain through the chimeric S-segment encoding sandfly fever phlebovirus NSs or a dominant-negative PKR.
    Nishiyama S, Slack OA, Lokugamage N, Hill TE, Juelich TL, Zhang L, Smith JK, Perez D, Gong B, Freiberg AN, Ikegami T.
    Virulence; 2016 Nov 16; 7(8):871-881. PubMed ID: 27248570
    [Abstract] [Full Text] [Related]

  • 49. Tissue tropism and target cells of NSs-deleted rift valley fever virus in live immunodeficient mice.
    Gommet C, Billecocq A, Jouvion G, Hasan M, Zaverucha do Valle T, Guillemot L, Blanchet C, van Rooijen N, Montagutelli X, Bouloy M, Panthier JJ.
    PLoS Negl Trop Dis; 2011 Dec 16; 5(12):e1421. PubMed ID: 22163058
    [Abstract] [Full Text] [Related]

  • 50. Genetic dissection of Rift Valley fever pathogenesis: Rvfs2 locus on mouse chromosome 11 enables survival to early-onset hepatitis.
    Batista L, Jouvion G, Simon-Chazottes D, Houzelstein D, Burlen-Defranoux O, Boissière M, Tokuda S, do Valle TZ, Cumano A, Flamand M, Montagutelli X, Panthier JJ.
    Sci Rep; 2020 May 26; 10(1):8734. PubMed ID: 32457349
    [Abstract] [Full Text] [Related]

  • 51. Mouse model for the Rift Valley fever virus MP12 strain infection.
    Lang Y, Henningson J, Jasperson D, Li Y, Lee J, Ma J, Li Y, Cao N, Liu H, Wilson W, Richt J, Ruder M, McVey S, Ma W.
    Vet Microbiol; 2016 Nov 15; 195():70-77. PubMed ID: 27771072
    [Abstract] [Full Text] [Related]

  • 52. Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge.
    Dodd KA, Bird BH, Metcalfe MG, Nichol ST, Albariño CG.
    J Virol; 2012 Apr 15; 86(8):4204-12. PubMed ID: 22345465
    [Abstract] [Full Text] [Related]

  • 53. Ultrastructural study of Rift Valley fever virus in the mouse model.
    Reed C, Steele KE, Honko A, Shamblin J, Hensley LE, Smith DR.
    Virology; 2012 Apr 15; 431(1-2):58-70. PubMed ID: 22687428
    [Abstract] [Full Text] [Related]

  • 54. Potent neutralizing human monoclonal antibodies protect from Rift Valley fever encephalitis.
    Connors KA, Chapman NS, McMillen CM, Hoehl RM, McGaughey JJ, Frey ZD, Midgett M, Williams C, Reed DS, Crowe JE, Hartman AL.
    JCI Insight; 2024 Aug 01; 9(18):. PubMed ID: 39088277
    [Abstract] [Full Text] [Related]

  • 55. Rift Valley Fever Virus Infection Causes Acute Encephalitis in the Ferret.
    Barbeau DJ, Albe JR, Nambulli S, Tilston-Lunel NL, Hartman AL, Lakdawala SS, Klein E, Duprex WP, McElroy AK.
    mSphere; 2020 Oct 28; 5(5):. PubMed ID: 33115835
    [Abstract] [Full Text] [Related]

  • 56. Pathogenicity of different strains of Rift Valley fever virus in Swiss albino mice.
    Tomori O, Kasali O.
    Br J Exp Pathol; 1979 Aug 28; 60(4):417-22. PubMed ID: 508592
    [Abstract] [Full Text] [Related]

  • 57. Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters.
    Westover JB, Mathis A, Taylor R, Wandersee L, Bailey KW, Sefing EJ, Hickerson BT, Jung KH, Sheridan WP, Gowen BB.
    Antiviral Res; 2018 Aug 28; 156():38-45. PubMed ID: 29864447
    [Abstract] [Full Text] [Related]

  • 58. The pathogenesis of Rift Valley fever.
    Ikegami T, Makino S.
    Viruses; 2011 May 28; 3(5):493-519. PubMed ID: 21666766
    [Abstract] [Full Text] [Related]

  • 59. Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.
    Ikegami T.
    Expert Rev Vaccines; 2017 Jun 28; 16(6):601-611. PubMed ID: 28425834
    [Abstract] [Full Text] [Related]

  • 60. Vaccination of alpacas against Rift Valley fever virus: Safety, immunogenicity and pathogenicity of MP-12 vaccine.
    Rissmann M, Ulrich R, Schröder C, Hammerschmidt B, Hanke D, Mroz C, Groschup MH, Eiden M.
    Vaccine; 2017 Jan 23; 35(4):655-662. PubMed ID: 28012779
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.